You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Comparative evaluation of the new FDA approved THxID™-BRAF test with high resolution melting and sanger sequencing
|
|---|---|
| Published in |
BMC Cancer, July 2014
|
| DOI | 10.1186/1471-2407-14-519 |
| Pubmed ID | |
| Authors |
Julie Marchant, Alain Mange, Marion Larrieux, Valérie Costes, Jérôme Solassol |
| Abstract |
Since patients diagnosed with BRAF V600E and V600K mutated advanced melanoma show response to treatment with MAP kinase inhibitors, several sensitive methods have been developed to determine the V600 allele status of melanoma patients. Vemurafenib (Zelboraf) and dabrafenib (Tafinlar) are specific BRAF V600 inhibitors recently approved by the US FDA as single agent treatments for unresectable or metastatic melanoma in patients with the BRAF V600 mutation. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Scientists | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 22 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 23% |
| Student > Master | 4 | 18% |
| Student > Bachelor | 4 | 18% |
| Other | 2 | 9% |
| Lecturer | 1 | 5% |
| Other | 2 | 9% |
| Unknown | 4 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 5 | 23% |
| Medicine and Dentistry | 4 | 18% |
| Biochemistry, Genetics and Molecular Biology | 2 | 9% |
| Business, Management and Accounting | 1 | 5% |
| Nursing and Health Professions | 1 | 5% |
| Other | 3 | 14% |
| Unknown | 6 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 April 2018.
All research outputs
#6,941,088
of 22,758,963 outputs
Outputs from BMC Cancer
#1,834
of 8,277 outputs
Outputs of similar age
#66,448
of 228,925 outputs
Outputs of similar age from BMC Cancer
#33
of 143 outputs
Altmetric has tracked 22,758,963 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 8,277 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 228,925 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 143 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.